The Coagulation System

Gerald A Soff MD

Chief, Classical Hematology Service
Sylvester Comprehensive Cancer Center,
University of Miami Health System
gas199@Miami.edu

UHealth
UNIVERSITY OF MIAMI HEALTH SYSTEM

UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

Disclosures

- Research Support (Past 2 years):
  - Amgen
  - Janssen Scientific Affairs
  - Sobi/Dova Pharmaceuticals
  - Anthos Therapeutics
  - Alpine Immune Sciences (Data Safety Monitoring Committee)

- Advisory Boards (Past 2 years)
  - Janssen Scientific Affairs
  - Sobi/Dova Pharmaceuticals
  - Sanofi
  - Novartis
  - Agios Pharmaceuticals.

Coagulation System



https://kidsfirstpediatrics.com
/babies-separation-anxiety/

What We'll Cover

1. Overview of Hemostasis and Coagulation
2. The "Classic Coagulation Cascade"
3. The Structure of the Coagulation Factors
4. Two Paths To Initiate Coagulation: Intrinsic and Extrinsic Systems
5. Overview of the Contact Phase:
   Initiation of Intrinsic Pathway
6. Fibrinogen: Fibrin
7. Limitations of the Classic Coagulation Cascade
8. Cell-Based Coagulation Model:
   Assembly Of Enzyme/Cofactor/Substrate Complex On Phospholipid Surface
9. "Cross-Over" of Extrinsic and Intrinsic Pathways
10. Activation of Factors V, VIII, XI, XIII by Thrombin: Thrombin Burst
11. Physiologic Anticoagulant Processes



Overview of Hemostasis and Coagulation

- Hemostasis: The processes of keeping the blood liquid in the vasculature.
  - Prevention of hemorrhage following vascular injury.
  - Prevention of excessive clotting (thrombosis) in the vasculature.
- Primary Hemostasis
  - Vascular forces (vasoconstriction) and platelet plug formation.
- Secondary Hemostasis
  - The coagulation factors leading to fibrin clot.
- Physiologic Anticoagulation processes
  - Neutralize activated factors and inhibit platelet function where vessels are intact.
  - Fibrinolysis



Major Components of Hemostasis



Vascular Injury

Hemostasis



Vasoconstriction

Platelet Plug Formation

Coagulation "Cascade"

Primary Hemostasis

Secondary Hemostasis

The "Classic Coagulation Cascade"
Early Understanding of Coagulation

- The first description of coagulation factors is attributed to Dr. Paul Morawitz in 1905.
- Factor I – Fibrinogen
- Factor II – Prothrombin
- Factor III – Thromboplastin Factor
  - (Tissue extract with Tissues Factor)
- Factor IV – Calcium



Assay of Coagulation Factors

- *In vitro* assays developed to test clotting times.
- The prothrombin time in 1935.
- Partial Thromboplastin Time in 1953.
- Led to identification of different coagulation factors.
- Plasma from a patient (and affected family members) with a hereditary bleeding disorder results in slower clotting *in vitro* in one or both assays.
  - The deficient factor was typically named with a Roman numeral and either a descriptive name or the proband family name.
  - (Examples: Hageman Factor = Factor XII, Antihemophilic Factor = Factor VIII)



Early Studies to Identify New Factors (New Deficiencies)

Plasma from patient with unknown bleeding disorder



Plasma from patient with known bleeding disorder (i.e. Hemophilia A)

- Perform Clotting Time on 1:1 mix.
- If the 1:1 mix "corrects," then the unknown sample has a different deficiency than the known deficiency.
- If the 1:1 mix remains prolonged, then the unknown sample has the same deficiency as the known deficiency.
- From the 1930s through the 1950s, most of the factors were identified in this way.
- Limitations: Inhibitors will interfere.

Original Publications Of Coagulation Cascade





Davie, E. W., and Ratnoff, O. D. "Waterfall sequence for intrinsic blood clotting." Science 1964: 145, 1310–1312

MacFarlane R.G. "An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier." Nature 1964; 202: 498-9

Note: Neither representation included Factor VII, of the Extrinsic Pathway!

"A clotting scheme for 1964"
The First Representation of the Current Cascade.



Macfarlane, RG. "A clotting scheme for 1964". Thrombosis et Diathesis Haemorrhagica, supplement. 17: 45-52, 1965.

Key Concepts From Original Publications Of The Coagulation Cascade

1. Coagulation involves a sequence of reactions.
2. Convention has shifted from names to Roman numerals.
3. Factors circulate in non-activated forms.
   a. Zymogens or pro-enzymes
   b. Pro-cofactors
4. Factors are activated by proteolytic cleavage by an “upstream” factor and in turn activate a “downstream” factor.
5. Terminology:
   a. Subscript “a” designates activated factor. (VIII → VIIIa)
   b. “i” refers to inactivated. (VIII → VIIIa →VIIIi)
6. A number of gaps, corrections, and open questions remained. (To be discussed below).



Contemporary Representation of the Coagulation Cascade



The Structure of the Coagulation Factors



The Zymogens:Enzymes



Factor IX Activation: Two Step Enzymatic Cleavage Site



- After activation, heavy and light chains remain covalently bound by disulfide bonds.
- Heavy chain facilitates binding to substrate.
- Gamma-Carboxyglutamic Acid (Gla) domain is in Heavy Chain.
- Light Chain contains the serine protease enzymatic domain.
- Substrate specificity determined by Heavy Chain binding and structure of the serine protease domain.
  - Emsley et al. Blood 2010;115:2569-2577

Serine Protease, Catalytic Domain



Serine, Histidine and Aspartic acid; amino acids in catalytic domain.

Cofactors

Factor VIII



Factor V



Dahlback B. JTH 15: 1241-1250, 2017
Camire & Bos. JTH, 7: 1951–1961, 2009

Vitamin K Mediated γ-Carboxylation of Glutamic Acid





Glutamic Acid:
Single negative charge



Gamma-Carboxyglutamic Acid (Gla):
Divalent negative charge. Can bind calcium

There Are Two Ways to Initiate Coagulation System *in Vitro*

Intrinsic Pathway/Contact Pathway:
Contact with a Negatively Charged Surface



XII, PK, HMWK

↓

XIIa

Extrinsic Pathway:
Addition of Tissue Thromboplastin (Tissue Factor and Phospholipid)

TF:VII

Auto-Activation

↓

VIIa



TF bound to cell surface

Overview of the Contact Phase: Initiation of Intrinsic Pathway



Contact System

- Activated by binding to a negatively charged surface.
- Factor XII
- Prekallikrein
- High Molecular Weight Kininogen
- Initiates the Intrinsic Pathway



Contact System



- **<u>Minimal contribution to hemostasis in physiologic situations.</u>**
- Deficiencies of the Contact Factors are not associated with bleeding tendency.
- Bradykinin (Derived from HMWK)
  - Role in inflammation, vascular tone.
- Increasing evidence that the Contact System has a role in pathological activation of coagulation and thrombosis.

“Contact system revisited: an interface between inflammation, coagulation, and innate immunity”



- **FXII deficiency is not physiologically associated with an increased bleeding risk.**
- **Contact system has a role in inflammation, complement system, fibrinolysis, and pathologic thrombosis.**

- **Polyphosphate (polyP) from activated platelets and bacteria can activate Factor XII.**
- **Neutrophil extracellular traps (NETs), chromatin extruded from activate.d neutrophils can activate the Contact System.**
- **F XIIa may increase vascular leak in allergic conditions.**
- Long AT, et al. J Thromb Haemost 2016; 14: 427–37.

Fibrinogen: Fibrin



Factor XIIIa (Transglutaminase): Cross-Link Fibrin

XIIIa: Cross-Links Fibrin Clot



From fibrinogen to fibrin Mesh



- (**A**) Fibrinogen D:E:D regions interact with thrombin-realizing fibrinopeptides (FpA and FpB)
- (**B**). Soluble fibrin is then activated by Factor XIIIa, permitting sulfide bonding to crosslink among fibrin, converting it to a
- (**C**) crosslinked fibrin polymer.

Rojas-Murillo, J.A. et al, Physical, Mechanical, and Biological Properties of Fibrin Scaffolds for Cartilage Repair. Int. J. Mol. Sci. 2022, 23, 9879. https://doi.org/10.3390/ijms23179879

Limitations of The Classic Coagulation Cascade

1) For years we have recognized the inconsistencies within these pathways to truly inform us of a patient's hemostatic system.
2) There are markedly different clinical manifestations of deficiencies of different factors, particularly within the Intrinsic Pathway.
   - Why do some deficiencies of the Intrinsic Pathway lead to severe bleeding, while other deficiencies do not cause bleeding?
3) The classic understanding that factors are activated in a "cascade," from top to bottom, is known to be incorrect.
4) Some enzymes have multiple substrates, and some factors can be activated by more than one enzyme.
5) In the following material, we will address these points and clarify the current understanding of the coagulation system.



Cell-Based Coagulation Model:
Assembly Of Enzyme/Cofactor/Substrate Complex On Phospholipid Surface



The Cell (Surface) Based Model Of Coagulation

Coagulation is "Best" understood as a series of membrane-bound complexes: enzyme/cofactor/substrate.



Three Complexes of "Classic Cascade"

Pathway	Complex	Enzyme	Cofactor	Substrate	Product
Intrinsic Pathway	Intrinsic Xase	IXa	VIIIa	X	Xa
Extrinsic Pathway	Extrinsic Xase	VII/VIIa	TF	X	Xa
Common Pathway	Prothrombinase	Xa	Va	II	IIa



"Cross-Over" of Extrinsic and Intrinsic Pathways



Clinical Manifestation Of Deficiencies of Factors Within the Intrinsic Pathway



- If this is a single pathway, why are different factor deficiencies associated with marked differences in clinical manifestations?
- This indicates our classic coagulation cascade is not the full story.

Two Alternative Substrates Of TF:VIIa Complex

Enzyme	Cofactor	Substrate	Product
VII/VIIa	Tissue Factor	X	Xa
		IX	IXa



Tissue Factor Pathway Inhibitor (TFPI)

- **TFPI inhibits activation of Factor X by TF:VIIa.**
- **Therefore, *In Vivo, the primary substrate of FVIIa is F IX.***
- ***In addition to activation of Factor X, the Extrinsic Pathway "Crosses Over" into the Intrinsic Pathway.***



Factor IX Can Be Activated By TF:VIIa or XIa



- **TF:VIIa has two substrates (IX or X).**
- **IX can be activated by two different enzymes (XIa or VIIa)**
- **The concept of a simple "cascade," with an ordered process of one factor activating the next, is not the complete picture.**
- ***In vivo, the "Common Pathway" starts with VIII and IX.***


XII, PK, HMWK
Tissue Factor
XI
Intrinsic Pathway
VII
Extrinsic Pathway
(Tissue Factor Pathway)
IX, VIII
X, V
Common Pathway
II
Fibrinogen (I)
Fibrin Monomer
XIII
Cross-Linked Fibrin Clot

The Thrombin Burst:
Activation of Factors V, VIII, XI, XIII by Thrombin:

https://commons.wikimedia.org/wiki/File:Most_distant_Gamma-ray_burst.jpg

Thrombin: Multiple Roles In Coagulation

- **How are Factors V and VIII activated?**
- **How is Factor XIII activated?**
- **Concept of Thrombin Burst: There are several steps within the coagulation cascade where thrombin participates in positive feedback processes, to greatly amplify the pro-coagulant state.**



Thrombin Feedback;
Activation of Factors V, VIII, XI, XIII



Procoagulant Activities of Thrombin

1. **Cleavage of Fibrinogen**
2. **Activation of Factor V**
3. **Activation of Factor VIII**
4. **Activation of Factor XI**
5. **Activation of Factor XIII**
6. **[Activation of Platelets]**

Role of Factor XI



- Factor XI can be activated by XIIa or Thrombin.
- Factor XI is a component of a positive feedback loop.
- Factor XI also links the Contact System with the core coagulation pathway.
- Factor XI deficiency is rarely associated with spontaneous bleeding.
- Inhibition of Factor XI is being explored as new option for therapeutic anticoagulation!

The Hemostatic Balance:
Physiologic Anticoagulation Processes



Vascular Endothelial Cells Present Anticoagulant Surface

- Vascular endothelial cells present anticoagulant surface.
- Disruption of endothelial surface exposes blood to Collagen and Subendothelial Matrix (procoagulants) leading to activation of coagulation.
- Deficiency of physiologic anticoagulants leads to activation of coagulation.



Physiologic Anticoagulation Processes on Endothelial Cells

Pathway	Activity	Effect
Heparan Sulfate (Glycosaminoglycan)	Heparan binds Antithrombin	Heparan:AT complex neutralizes coagulation enzymes
Thrombomodulin & Endothelial Protein C Receptor	Thrombomodulin binds Thrombin EPCR binds protein C	Thrombin:TM complex has reduced procoagulant activity. Activates protein C which inactivates Cofactors
Tissue Factor Pathway Inhibitor	TFPI inhibits direct activation of Factor X by TF:VIIa complex	Directs TF:VIIa activity towards activation of F IX to IXa.
CD39-Ecto ADPase	Degrades ADP	Reduced ADP, reduced platelet activation
NO Synthase	Synthesis of Nitric Oxide	Relaxes smooth muscle and inhibits platelet activation
Cyclooxygenase 2	Synthesis of Prostacyclin (PGI2)	Relaxes smooth muscle and inhibits platelet activation



Antithrombin

Antithrombin:
Inactive Conformation

Thrombin

Antithrombin, in fluid phase is unable to bind thrombin or other enzymes.

Heparan Sulfate
(Glycosaminoglycan)



Endothelial Cell

Antithrombin Binds to Glycosaminoglycan



- AT undergoes a conformational change when bound to Heparan or Heparin.
- Heparin:AT complex has high affinity for thrombin and other enzymes of the coagulation system.
- Thrombin:Antithrombin Complex Forms.

Antithrombin: Glycosaminoglycan

Thrombin:Antithrombin Complex Dissociates from Glycosaminoglycan and is cleared in the liver.

Heparan Sulfate (Glycosaminoglycan)



Protein C/Protein S/Thrombomodulin System

- Constituents:
  - Protein C
  - Protein S
  - Thrombomodulin
  - Endothelial cell protein C receptor (EPCR)
- Activated Protein C (With cofactor Protein S) inactivates FVa and FVIIIa, the cofactors of the cascade.
- EPCR localizes Protein C/Ca to endothelial cell surface.
  - May have non-coagulation roles.



Protein C/Protein S/Thrombomodulin



IIa
(Procoagulant)

- **Thrombin, in fluid phase, is a potent procoagulant.**
- **i.e. Cleaves fibrinogen, etc.**



EPCR: Endothelial Cell Protein C Receptor

Protein C/Protein S/Thrombomodulin



- Thrombomodulin (TM) is expressed on normal endothelial cells.
- When Thrombin binds to TM, thrombin loses its procoagulant activity and gains anticoagulant activity.

EPCR: Endothelial Cell Protein C Receptor

Protein C/Protein S/Thrombomodulin

- Thrombin:Thrombomodulin complex cleaves and activates Protein C.
- (Protein C localizes to Endothelial Cell Protein C Receptor).



EPCR: Endothelial Cell Protein C Receptor

Protein C/Protein S/Thrombomodulin

- **Activated Protein C, with its cofactor Protein S, cleaves and inactivates Factors Va and VIIIa.**



EPCR: Endothelial Cell Protein C Receptor

Fibrinolytic Pathway

- Plasminogen
  - Activated to Plasmin (a serine proteinase)
  - Plasmin proteolyzes fibrin and fibrinogen
- Plasminogen Activators
  - t-PA (Tissue-Plasminogen Activator)
    - Localizes to fibrin clot
  - u-PA (Urokinase-Plasminogen Activator)
    - Localizes to cell membrane uPA receptor.
  - Released by endothelial cells.
- Inhibitors/Serpins
  - PAI-1, PAI-2; Plasminogen Activator Inhibitors
  - α2-Antiplasmin.



Fibrinolytic Pathway:
T-PA, Fibrin Clot Based Activation



Fibrinolytic Pathway: U-PA/U-PAR, Cell Based Activation

- U-PA: Urokinase (Plasminogen Activator)
- U-PAR: Urokinase Receptor



Fibrinolytic Pathway: Inhibitors

- PAI-1, PAI-2: Plasminogen Activator Inhibitors 1 and 2
- α2-AP: Alpha 2 antiplasmin




Thank You!